In this article the authors charted memory B cell receptor-encoded antibodies from 19 COVID-19 convalescent subjects against SARS-CoV-2 spike (S) and found 7 major antibody competition groups against epitopes recurrently targeted across individuals.

The objective of this study was to describe myocarditis presenting after COVID-19 vaccination within the Military Health System.

The objective of this study was to estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes.

The objective of this randomized clinical trial was to determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14.

This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States.

In this article the authors report cryo-EM structures of the full-length spike (S) trimers of the B.1.1.7 and B.1.351 variants, as well as their biochemical and antigenic properties.

In this article the authors combine cryo-EM, binding and computational analyses to study variant spikes, including one that was involved in transmission between minks and humans, and others that originated and spread in human populations.

A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429), originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain (NTD), and L452R in the receptor-binding domain (RBD).

In this article the authors identify four receptor-binding domain targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants.

In this article the authors isolated an infectious Delta strain from a traveller returning from India.

In this double-blind, randomised, placebo-controlled phase 3 trial the authors present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.

In this article the authors assessed whether azithromycin is effective in reducing hospital admission in patients with mild-to-moderate COVID-19.

In this systematic review and meta-analysis, the authors searched various databases between Jan 1, 2020, and March 5, 2021, for original studies reporting data on COVID-19 outcomes in patients with psychiatric disorders compared with controls.

In this article the authors conducted an online survey of people with suspected and confirmed COVID-19, distributed via COVID-19 support groups.

In this article the authors conducted a single-center, open-label, non-randomized, Phase 1 trial in India between July 2020 and October 2020.